Effects of Bosentan on the Skin Temperature of Hands and Feet in Patients with Connective Tissue Diseases Complicated with Raynauds Phenomenon: A Prospective, Open-Label, Uncontrolled, Single-Center Study

Effects of Bosentan on the Skin Temperature of Hands and Feet in Patients with Connective Tissue Diseases Complicated with Raynauds Phenomenon: A Prospective, Open-Label, Uncontrolled, Single-Center Study

Yuji Akiyama

Contact

Kazuhiro Yokota

Contact

Kyoichi Nakajima

Contact

Yoshihiro Yoshida

Contact

Yasuto Araki

Contact

Hiroshi Kajiyama

Contact

Yu Asanuma Funakubo

Contact

Kojiro Sato

Contact

Toshihide Mimura

Contact

α Saitama Medical University

Effects of Bosentan on the Skin Temperature of Hands and Feet in Patients with Connective Tissue Diseases Complicated with Raynauds Phenomenon: A Prospective, Open-Label, Uncontrolled, Single-Center Study

Article Fingerprint

ReserarchID

3XUV6

AI TAKEAWAY

Connecting with the Eternal Ground

References

23 Cites in Article

Reference Format

Masashi Yanagisawa,Hiroki Kurihara,Sadao Kimura,Yoko Tomobe,Mieko Kobayashi,Youji Mitsui,Yoshio Yazaki,Katsutoshi Goto,Tomoh Masaki (1988). A novel potent vasoconstrictor peptide produced by vascular endothelial cells.
Sohita Dhillon (2009). Bosentan.
Y Shirai,H Yasuoka,Y Okano,T Takeuchi,T Satoh,M Kuwana (2012). Clinical characteristics and survival of Japanese patients with connective tissue disease and pulmonary arterial hypertension: a singlecenttre cohort.
M Vayssairat,French (1996). Microcirculation Society Multicentre Group for the Study of Vascular Acrosyndromes. Controlled multicenter double blind trial of an oral analog of prostacyclin in the treatment of primary Raynaud's phenomenon.
M Hettema,D Zhang,H Bootsma,Cgm Kallenberg (2007). Bosentan therapy for patients with severe Raynaud's phenomenon in systemic sclerosis.
Masanori Funauchi,K Kishimoto,H Shimazu,Y Nagare,S Hino,T Yano,K Kinoshita (2009). Effects of bosentan on the skin lesions: an observational study from a single center in Japan.
N Giordano,L Puccetti,P Papakostas,N Dipietra,F Bruni,A Pasqui (2010). Bosentan treatment for Raynaud's phenomenon and skin fibrosis in patients with systemic sclerosis and pulmonary arterial hypertension: An open-label, observational, retrospective study.
V Nguyen,K Eisendle,I Gruber,B Hugl,D Reider,N Reider (2010). Effect of the dual endothelin receptor antagonist bosentan on Raynaud's phenomenon secondary to systemic sclerosis: a double-blind prospective, randomized, placebo-controlled pilot study.
Edoardo Rosato,Ilenia Molinaro,Federica Borghese,Carmelina Rossi,Simonetta Pisarri,Felice Salsano (2010). Bosentan Improves Skin Perfusion of Hands in Patients with Systemic Sclerosis with Pulmonary Arterial Hypertension.
T Moore,A Vail,A Herrick (2007). Assessment of digital vascular structure and function in response to bosentan in patients with systemic sclerosis-related Raynaud's phenomenon.
S Parisi,C Peroni,A Lagana,M Scarati,F Ambrogio,M Bruzzone,E Fusaro (2013). Efficacy of ambrisentan in the treatment of digital ulcers in patients with systemic sclerosis: a preliminary study.
A Masi (1980). Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classication of systemic sclerosis (scleroderma).
E Tan,A Cohen,J Fries,A Masi,D Mcshane,N Rothfield (1982). The 1982 revised criteria for the classification of systemic lupus erythematosus (SLE).
R Kasukawa,T Nishimaki,T Takagi,S Miyawaki,R Yokohari,T Tsunematsu (1988). Pulmonary hypertension in connective tissue disease. Clinical analysis of sixty patients in multi-institutional study.
A Bohan,J Peter (1975). Polymyositis and dermatomyositis.
Richard Rodeheffer,James Rommer,Fredrick Wigley,Craig Smith (1983). Controlled Double-Blind Trial of Nifedipine in the Treatment of Raynaud's Phenomenon.
B Coleiro,S Marshall,C Denton,K Howell,A Blann,K Welsh,C Black (2001). Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine.
Y Akiyama,S Ohno,T Asaoka,T Katagiri,M Takeishi,H Omata (2001). The combination therapy with sarpoglerate hydrochloride and kampo medicine (Oren-gedoku-to or Toki-shakuyaku-san) for Raynaud's phenomenon.
M Ramos-Casals,P Brito-Zeron,N Nardi,G Claver,G Risco,F Parraga (2004). Successful treatment of severe Raynaud's phenomenon with bosentan in four patients with systemic sclerosis.
N Selenko-Gebauer,N Duschek,G Minimair,G Stingl,F Karlhofer (2006). Successful treatment of patients with severe secondary Raynaud's phenomenon with the endothelin receptor antagonist bosentan.
Padmanabha Shenoy,Sudeep Kumar,Lalan Jha,Sunil Choudhary,Uttam Singh,Ramnath Misra,Vikas Agarwal (2010). Efficacy of tadalafil in secondary Raynaud’s phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial.
Matthieu Roustit,Sophie Blaise,Yannick Allanore,Patrick Carpentier,Evren Caglayan,Jean-Luc Cracowski (2013). Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials.
Claudio Corallo,Maurizio Cutolo,Bashar Kahaleh,Gianluca Pecetti,Antonio Montella,Chiara Chirico,Stefano Soldano,Ranuccio Nuti,Nicola Giordano (2013). Bosentan and macitentan prevent the endothelial-to-mesenchymal transition (EndoMT) in systemic sclerosis: in vitro study.

Download References

Funding

No external funding was declared for this work.

Conflict of Interest

The authors declare no conflict of interest.

Ethical Approval

No ethics committee approval was required for this article type.

Data Availability

Not applicable for this article.

How to Cite This Article

Yuji Akiyama. 2015. \u201cEffects of Bosentan on the Skin Temperature of Hands and Feet in Patients with Connective Tissue Diseases Complicated with Raynauds Phenomenon: A Prospective, Open-Label, Uncontrolled, Single-Center Study\u201d. Global Journal of Medical Research - F: Diseases GJMR-F Volume 15 (GJMR Volume 15 Issue F2): .

More Citation Formats

Select Citation Style:

Download Citation

Download Article

GJMR Volume 15 Issue F2
Pg. 7- 15

Explore Journals Explore Volume Read This Issue

Journal Specifications

Crossref Journal DOI 10.17406/gjmra

Print ISSN 0975-5888

e-ISSN 2249-4618

Keywords

Not Found

Classification

GJMR-F Classification: NLMC Code: WD 375

Submission ReceivedApril 14, 2015
Peer Review Double Blind
Handling Editor
Accepted May 4, 2015
Published May 15, 2015

Version of record

v1.2

Issue date

May 29, 2015

Language

Experiance in AR

Explore published articles in an immersive Augmented Reality environment. Our platform converts research papers into interactive 3D books, allowing readers to view and interact with content using AR and VR compatible devices.

View in VR

Read in 3D

Your published article is automatically converted into a realistic 3D book. Flip through pages and read research papers in a more engaging and interactive format.

View in 3D

Article Matrices

Total Score: 154

Country: Japan

Subject: Global Journal of Medical Research - F: Diseases

Authors: Yuji Akiyama, Kazuhiro Yokota, Kyoichi Nakajima, Yoshihiro Yoshida, Yasuto Araki, Hiroshi Kajiyama, Yu Asanuma Funakubo, Kojiro Sato, Toshihide Mimura (PhD/Dr. count: 0)

View Count (all-time): 182

Total Views (Real + Logic): 4191

Total Downloads (simulated): 2137

Publish Date: 2015 05, Fri

Monthly Totals (Real + Logic):

Month 1: 66 views
Month 2: 31 views
Month 3: 36 views
Month 4: 65 views
Month 5: 23 views
Month 6: 22 views
Month 7: 43 views
Month 8: 26 views
Month 9: 25 views
Month 10: 39 views
Month 11: 30 views
Month 12: 15 views
Month 13: 35 views
Month 14: 35 views
Month 15: 16 views
Month 16: 29 views
Month 17: 49 views
Month 18: 13 views
Month 19: 42 views
Month 20: 39 views
Month 21: 42 views
Month 22: 26 views
Month 23: 21 views
Month 24: 46 views
Month 25: 34 views
Month 26: 37 views
Month 27: 36 views
Month 28: 46 views
Month 29: 35 views
Month 30: 37 views
Month 31: 44 views
Month 32: 31 views
Month 33: 30 views
Month 34: 38 views
Month 35: 16 views
Month 36: 18 views
Month 37: 32 views
Month 38: 13 views
Month 39: 25 views
Month 40: 40 views
Month 41: 20 views
Month 42: 39 views
Month 43: 14 views
Month 44: 21 views
Month 45: 20 views
Month 46: 17 views
Month 47: 44 views
Month 48: 44 views
Month 49: 39 views
Month 50: 19 views
Month 51: 30 views
Month 52: 20 views
Month 53: 11 views
Month 54: 22 views
Month 55: 30 views
Month 56: 18 views
Month 57: 18 views
Month 58: 37 views
Month 59: 31 views
Month 60: 25 views
Month 61: 28 views
Month 62: 27 views
Month 63: 23 views
Month 64: 35 views
Month 65: 17 views
Month 66: 25 views
Month 67: 43 views
Month 68: 43 views
Month 69: 19 views
Month 70: 23 views
Month 71: 33 views
Month 72: 25 views
Month 73: 36 views
Month 74: 25 views
Month 75: 13 views
Month 76: 22 views
Month 77: 47 views
Month 78: 41 views
Month 79: 28 views
Month 80: 18 views
Month 81: 40 views
Month 82: 33 views
Month 83: 31 views
Month 84: 42 views
Month 85: 25 views
Month 86: 36 views
Month 87: 16 views
Month 88: 38 views
Month 89: 32 views
Month 90: 34 views
Month 91: 43 views
Month 92: 38 views
Month 93: 38 views
Month 94: 30 views
Month 95: 24 views
Month 96: 16 views
Month 97: 39 views
Month 98: 19 views
Month 99: 29 views
Month 100: 37 views
Month 101: 40 views
Month 102: 15 views
Month 103: 34 views
Month 104: 20 views
Month 105: 35 views
Month 106: 25 views
Month 107: 43 views
Month 108: 48 views
Month 109: 32 views
Month 110: 36 views
Month 111: 26 views
Month 112: 29 views
Month 113: 38 views
Month 114: 17 views
Month 115: 26 views
Month 116: 30 views
Month 117: 18 views
Month 118: 22 views
Month 119: 21 views
Month 120: 29 views
Month 121: 40 views
Month 122: 39 views
Month 123: 36 views
Month 124: 39 views
Month 125: 23 views
Month 126: 41 views
Month 127: 45 views
Month 128: 27 views
Month 129: 42 views
Month 130: 33 views
Month 131: 54 views

Total Views: 4191

Total Downloads: 2137

2026 Trends

Published Article

Abstract not found

Our website is actively being updated, and changes may occur frequently. Please clear your browser cache if needed. For feedback or error reporting, please email [email protected]